The Scientific Advisory Board
Each institute of the Max Planck Society has an advisory board as the main external evaluation instrument of its scientific work. As a rule, the board consists of eight to ten members, who mostly do not belong to the Max Planck Society, but are scientists from universities and other research institutions in Germany and abroad.
Every three years the scientific advisory board undertakes an evaluation of the research achievements of the institute. The results and insights gained from this are an important basis for planning further scientific developments and for managing the resources of the Max Planck Society as a whole.
The Members of the Scientific Advisory Board of the Max Planck Institute for Molecular Biomedicine:
- Dr. Vania Braga, South Kensington Campus, Imperial College London, London, United Kingdom
- Dr. Kevin Chalut, Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
- Prof. Dr. Christopher C. W. Hughes, Department of Molecular Biology and Biochemistry, University of California, Irvine, USA
- Dr. Danijela Matic Vignjevic, Institut Curie/UMR144, Paris, France
- Prof. Dr. Anthony Oro, Department of Dermatology, Stanford University, Stanford, USA
- Prof. Dr. Tatiana V. Petrova, Department of Oncology, CHUV and University of Lausanne, Epalinges, Switzerland (Chair)
- Prof. Dr. Stefan Rose-John, Institute of Biochemistry, Kiel University, Kiel, Germany
- Prof. Dr. Karina Yaniv, Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel
(As of April 2022)